

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61B 5/08, 5/05		A1	(11) International Publication Number: WO 97/37591
			(43) International Publication Date: 16 October 1997 (16.10.97)
(21) International Application Number: PCT/SG97/00013		(81) Designated States: AU, CA, CN, JP, KR, RU, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 7 April 1997 (07.04.97)			
(30) Priority Data: 629,420 8 April 1996 (08.04.96) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): RHEO- GRAPHIC PTE LTD [SG/SG]; 17 Jurong Port Road, Singapore 619092 (SG).			
(72) Inventors; and (75) Inventors/Applicants (for US only): SCHOOKIN, Sergei, I. [RU/RU]; Yuriyevskiy pr., 22 bld. 1, app 21, Moscow, 111020 (RU). ZUBENKO, Viatcheslav G. [RU/RU]; Iz- mailovskoe sh., 45, app 14, Moscow, 105187 (RU). BE- LIAEV, Konstantin R. [RU/RU]; Fost'valnaya st. 5, app 115, Moscow, 125565 (RU). MOROZOV, Aleksandr A. [RU/RU]; Dezhneva st. 6 bld. 2, app 127, Moscow, 129642 (RU). YONG, Wen, H. [SG/SG]; 43 Poh Huar Drive, Sin- gapore 546628 (SG).			
(74) Agent: CHAN & RAVINDRAN (PATENTS) PTE. LTD.; P.O. Box 2988, Raffles City, Singapore 9117 (SG).			

(54) Title: NON-INVASIVE MONITORING OF HEMODYNAMIC PARAMETERS USING IMPEDANCE CARDIOGRAPHY

(57) Abstract

A method and apparatus for determination of heart rate, heart stroke volume, and cardiac output from thoracic bioimpedance signals and electrocardiograms. A unique bioimpedance electrode arrangement is employed, and the bioimpedance signals are corrected for gain phase-frequency distortion through the use of sinusoidal test signals through the measuring or detection electrodes to identify distortions and correct for same during actual measurements. Time-derivative bioimpedance signals are employed, the power spectrum calculated, and a novel autoconvolution procedure used to emphasize the heart rate harmonic. Breath waves and other signals not indicative of the patient's cardiocycles are removed. Left ventricular ejection time is derived from the bioimpedance signals, and an improved version of Kubicek's equation is employed to derive heart stroke volume and thus cardiac output.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GD	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NON-INVASIVE MONITORING OF HEMODYNAMIC PARAMETERS USING IMPEDANCE CARDIOGRAPHY

5

TECHNICAL FIELD

The present invention relates generally to cardiac monitoring and specifically to the determination of heart rate (HR), heart stroke volume (SV), and cardiac output (CO) according to detection and complex analyses of thoracic bioimpedance and electrocardiograph (ECG) signals, which permit precise detection of the start of
10 left ventricular ejection.

BACKGROUND ART

Heart rate is the number of times the heart beats per minute. Heart stroke volume is the volume of blood pumped during each heart stroke. Cardiac output is the volume of blood pumped in one minute and is generally considered to be the
15 most significant gauge of cardiac fitness. Physicians must frequently rely upon such cardiac parameters to diagnose heart disease, to assess a patient's overall health, to determine the most appropriate method of treatment, and to quickly discover sudden lapses in cardiac performance.

The currently existing methods for measuring cardiac output and other
20 cardiac parameters may be divided into two categories: invasive and noninvasive. The invasive methods require that a medical practitioner insert a measuring device into the patient's body, such as a catheter in the throat, and present numerous disadvantages to both patient and physician. The patient must often endure substantial pain and discomfort and the physician must perform a relatively
25 complicated procedure and occasionally expose himself or herself to the risk of contact with infectious blood. The noninvasive methods currently in use represent a major advancement, but still have significant shortcomings. Most take measurements using ultrasound, phonocardiography, or electrical bioimpedance in order to calculate cardiac parameters.

30 The methods which employ bioimpedance measurement involve placing a plurality of electrodes on a patient's skin (predominantly in the thoracic region), generating a high frequency, low amplitude electric current from certain of the electrodes into the patient's body, measuring the changes in the electrical impedance

-2-

of the patient's tissue over time, and correlating the changes in electrical impedance with cardiac parameters.

The manner of arranging the electrodes on the patient's body plays an important part in the relative accuracy of the ultimate cardiac parameter measurements. Due to various anatomical factors, electrodes must be placed over certain areas of the body to achieve optimum correlation between measured changes in bioimpedance and cardiac parameters. Many of the electrode configurations currently in use fail to adequately take into account the paths followed by the lines of electrical potential through the thorax and thus create a distortion in the cardiac measurement. Moreover, a few electrode arrangements require the use of band electrodes, e.g., influencing band electrodes A, B and measuring band electrodes C, D each having a width "n" (see FIG. 1). These band electrodes typically wrap around a patient like a belt and further limit access to the patient, an especially undesirable condition during resuscitation procedures. The movements associated with respiration also make band electrodes very inconvenient when placed on the neck and chest.

Perhaps the most significant problem with the presently existing bioimpedance methods is the imprecise mathematical derivation of cardiac parameters from bioimpedance measurements. The ventricular ejection time (VET) is a measurement of the time between the opening and closing of the aortic valves during the systole-diastole cycle of the heartbeat and it must be calculated as an intermediate step in determining cardiac stroke volume. The prior art does not teach a method for determining ventricular ejection time with sufficient accuracy. Furthermore, the prior art fails to account for the fact that VET is not a single event. In reality, there is actually a left VET and a right VET. It has been shown that the time-derivative impedance signal is actually proportional to the peak aortic blood flow ejected by the left ventricle. The measurements of left VET and right VET for most patients are generally very close, but even slight differences between them can create errors in bioimpedance readings under the methods currently in use.

Furthermore, the classic algorithm for ejection start time is elaborate, and works well only for healthy patients at rest. It is not accurate for patients under physical training or other physical stress, or for critically ill patients, such as those typically in intensive care units.

-3-

The conventional equation for deriving stroke volume from bioimpedance signals has become known as the Kubicek equation and is given as follows:

$$SV = R(L/Z_0)^2 \cdot \Delta Z$$

- 5 where SV is heart stroke volume, R is blood resistivity, L is the distance between the inner and outer voltage sensing electrodes, Z_0 is the mean thoracic impedance determined from the inner voltage sensing electrodes, and ΔZ is the impedance change due to blood influx. Kubicek's estimation of this value is

$$\Delta Z = (VET) (dZ/dt)_{max}$$

- 10 where VET is the combined left and right ventricular ejection time, and $(dZ/dt)_{max}$ is the maximum negative slope change of the time-differentiated impedance signal. Most bioimpedance cardiac monitoring systems use some form of the Kubicek equation.

- Without further refinement, however, the Kubicek equation frequently gives
 15 inaccurate measurements. This is due in part to the fact that both ventricles contribute to impedance changes, and so Kubicek's calculated ejection time (VET) cannot be associated with a particular, specifically the left, critical ventricle. Concurrently, Kubicek's ΔZ estimation becomes invalid when strong left-right ventricles asynchronism is observed. As a result, Kubicek's SV calculation is often
 20 proportional to, but not equal to, the actual heart stroke volume and must therefore be multiplied by some correlating constant. In addition, the prior art does not disclose a method for adjusting R in accordance with the fluctuation of a patient's hematocrit (red blood cell count). The adjustment of R is especially important in patients undergoing blood infusion.

- 25 Many of the methods for bioimpedance cardiography require that the patient hold his or her breath during each measurement because respiration causes interference in the bioimpedance signal. Such methods are inconvenient for some patients and completely useless for other patients who are unconscious or otherwise unable to hold their breath. Some of the more recent methods include signal

processing capability to enhance the signal, to identify the effects of respiration, and to eliminate defective signals so that errors are not introduced into the final calculations. Effective signal processing is generally the key to insuring accuracy in bioimpedance cardiography and improvements in this area can represent significant

5 advances in the art.

DISCLOSURE OF INVENTION

The invention discloses a method of measuring hemodynamic parameters using a novel combination of bioimpedance cardiography and electrocardiography
10 which allows medical practitioners to obtain an accurate, substantially continuous assessment of a patient's cardiac performance. The bioimpedance and electrocardiogram signals are measured over a common time interval of interest, preferably more than ten (10) heartbeats.

The apparatus of the invention uses a series of spot electrodes adapted for
15 placement on the surface of the patient's skin to generate a high frequency, low amplitude electrical current through the thorax of the patient and to measure changes in the bioimpedance. The disclosed electrode configuration takes advantage of the physiological arrangement of electrical potential power lines in the body.

Concurrently, a method of the invention may utilize electrocardiography to
20 enhance the accuracy of the ejection time detection from the measured bioimpedance signal. The electrocardiogram can be obtained in any standard position, well known in electrocardiography. To eliminate the overall quantity of electrodes at the patient's skin, this invention may use the same set of electrodes for bioimpedance and ECG measurements (see FIG. 6B).

25 The invention may also involve the step of continuously adjusting the calculation of cardiac parameters according to changes in the red blood cell count and according to varying bodily compositions of different patients, and can thus be used under a variety of different circumstances without a loss of accuracy.

In addition, the invention comprises a method of improved bioimpedance
30 signal processing. It may employ a computer system to analyze the both the bioimpedance signal and the electrocardiogram in a variety of ways to provide an accurate report of cardiac parameters. The computer system may be used to make corrections in the gain-phase-frequency characteristics caused by the transducers

-5-

used to measure the bioimpedance and ECG. The computer system communicates a sinusoidal test curve to the transducer receiver and may then measure and record the gain-phase-frequency distortions created by the receiver. The "real" bioimpedance signals subsequently received by the computer system through that transducer may

5 pass through filters which remove the transducer's characteristic distortions as well as breath and movement artifacts. Accuracy of gain-frequency response and phase-frequency response may be corrected to within 5%.

The invention may further comprise a method of signal processing the ECG signal to determine QRS complexes (characteristic heartbeat waveforms) and check
10 point positions for use in refining the bioimpedance signal calculations. The signal processing may involve sampling the measured ECG signal and filtering it to highlight the positions of the QRS complexes. Peak-to-peak amplitudes may be recorded and a threshold amplitude may be calculated. Defect-free QRS complexes are selected using the threshold amplitude. Finally, additional analysis of selected
15 events may be performed to determine check point positions.

The computer system of the invention may derive and save in memory a time-derivative bioimpedance signal. The curve generated by the time-derivative bioimpedance signal may be plotted with respect to time and represents repeated cardiocycles. The power spectrum of the bioimpedance signal may be calculated
20 with discrete Fourier transforms and studied to estimate the patient's heart rate and to identify the fronts of each cardiocycle. A novel mathematical autoconvolution procedure may be used to emphasize the heart rate harmonic in the time-derivative bioimpedance signal.

Breath waves may be removed by generating an envelope within the power
25 spectrum in which cardiocycle signals should be found and then removing those signals which lie outside the envelope.

The computer system may employ a new method of deriving the effective left ventricular ejection time (ELVET) from bioimpedance signals and ECG signals. In particular, precise detection of the ejection start time is based on complex
30 analyses of the bioimpedance and ECG signals. The derivation of ELVET is a detailed, multi-step analysis which involves finding various points on the time-derivative bioimpedance curve based on corresponding points on the ECG curve and determining which of these points most accurately reflect cardiac events. It requires

-6-

making a variety of mathematical calculations, including making approximations for differentials of the time-derivative bioimpedance curve.

In healthy patients there is very little left-right ventricular asynchronism or asynchronism between opening of left and right ventricle valves. However, in

5 seriously ill patients, the Kubicek equation generally underestimates the time-derivative bioimpedance signal due to left-right ventricular asynchronism. The computer system, in accordance with the invention, automatically adjusts for signals which exhibit asynchronism between opening of left and right ventricle valves to calculate the correct value of ΔZ , the impedance changes due to blood influx.

10 After the computer system calculates ELVET and ΔZ , it employs an improved form of Kubicek's equation to derive Heart Stroke Volume from ELVET, blood resistivity, the patient's specific body constitution, and the maximum bioimpedance change. The computer system analyzes the time-derivative bioimpedance signal to eliminate cardiocycles with certain aberrations.

15 Finally, the invention further comprises a method of detecting valid cardiocycles.

BRIEF DESCRIPTION OF DRAWINGS

20 FIG. 1 is a schematic depiction of a band-type electrode arrangement on a patient;

FIGS. 2A, 2B, and 2C schematically depict spot-type electrode placements according to the present invention;

FIG. 3A depicts anatomical zones of interest for placement of measuring chest electrodes according to the present invention;

25 FIG. 3B illustrates the positioning of the anatomical zones of FIG. 3 on a patient;

FIG. 4 illustrates the structure of an individual chest electrode according to the present invention;

30 FIG. 5A is a graph of the gain versus frequency characteristics of an A-filter according to the invention employed for signal differentiations and harmonics suppression;

FIG. 5B is a graph of the gain versus frequency response of a B-filter as employed in the present invention to highlight the fronts of cardiocycles;

-7-

FIG. 5C is a graph of filtration employed to remove breath waves' power spectrum from the summary (breath and cardiowave) power spectrum in the present invention;

FIG. 6A is a branch chart of the methodology of the present invention;

5 FIG. 6B is a flow chart of signal processing and depicting the apparatus employed in performing the method of the present invention;

FIG. 7A depicts the gain-frequency characteristic $G(f)$ of a bioimpedance transducer according to the present invention;

FIG. 7B depicts the phase frequency characteristic $P(f)$ of a bioimpedance
10 transducer of the present invention;

FIG. 7C depicts the gain frequency characteristic $\frac{1}{G(f)}$ of an "R" or restoring filter corresponding to the characteristic of FIG. 7A as used for GPF corrections according to the instant invention;

FIG. 7D depicts the phase frequency characteristic $-P(f)$ of an "R" or
15 restoring filter corresponding to the characteristic of FIG. 7B as used for GPF corrections according to the instant invention;

FIG. 8A depicts the resulting gain frequency characteristic $G(f)$ of a transducer signal as corrected by an R-filter according to the present invention;

FIG. 8B depicts the resulting phase frequency characteristic $P(f)$ of a
20 transducer signal as corrected by an R-filter according to the present invention;

FIG. 9 is an illustration of a time-derivative bioimpedance signal generated according to the present invention, plotted with respect to time and depicting exemplary impedance changes due to blood influx (ΔZ) over the same time period;

FIG. 10 is a graph of the electric potential traversing the heart of a patient
25 plotted with respect to time (electrocardiogram), depicting the peak-to-peak amplitudes (E_1 - front, E_2 - back) of the QRS complex in a single heartbeat;

FIG. 11 is a scatter diagram of all peaks measured in an electrocardiogram over a period of ten seconds. The coordinates of the graph are (E_1 , E_2), and the QRS complexes are within the dotted circle in the lower right hand corner;

30 FIG. 12 is a graph of the ECG signal and the time-differentiated bioimpedance signal plotted against time indicating check-points P, S₁, and S₂ on the

ECG signal, relative to check-points Q, S, and A on the time-differentiated bioimpedance signal;

FIG. 13 is a graph of ECG, bioimpedance $Z(t)$, and time-differentiated bioimpedance dZ/dt , signals with respect to time indicating the bioimpedance difference between the S and Q points, Z_{s-q} in a healthy patient;

FIG. 14 is a graph of ECG, bioimpedance $Z(t)$, and time-differentiated bioimpedance dZ/dt , signals with respect to time indicating the bioimpedance difference between the S and Q points, Z_{s-q} in a patient with ischemic heart disease; and

FIG. 15 is a graphic depiction of the correlation of the inventive method of determining ELVET to an ideal, ultrasound determination in comparison to the classic Kubicek algorithm methodology.

BEST MODES FOR CARRYING OUT THE INVENTION

The first step in the present invention involves taking bioimpedance measurements over segments of tissue on a patient's body. Electrodes must be placed at appropriate points on the surface of the skin to generate a high frequency, low amplitude electric current and to detect changes in the generated current after it passes through the segments of tissue (see FIGS. 2A, 2B, 3 and 4). The electrodes are "spot electrodes" rather than "band electrodes" in order to maximize the free area on the patient's body. The spot electrodes are preferably of the disposable, one-use type. The patient thus has increased freedom of movement and medical practitioners have more access to the patient's skin for other medical procedures, such as the introduction of catheters and the administration of anesthesia.

The bioimpedance electrode system employs a total of six electrodes: a pair of detecting (measuring) electrodes 20 at the xiphoid process level, a pair of detecting (measuring) electrodes 22 positioned laterally on the neck, an influencing electrode 24 on the left leg, and an influencing electrode 26 on the forehead.

The influencing electrodes 24, 26 may be standard ECG spot electrodes with a contact area of 2 centimeters by 2 centimeters (cm). The upper influencing electrode 26 is preferably placed on the middle of the forehead, at the mid-line thereof. The lower influencing electrode 24 is preferably placed on the left knee or somewhere below the left knee such as the left foot. If necessary, the lower

-9-

influencing electrode 24 may also be placed above the knee level, provided that the following condition is satisfied:

$$L > 5R,$$

where L is the distance between influencing electrodes and R is the radius of the chest. The left leg is used instead of the right leg to account for the anatomic asymmetry of the heart. The physiological positioning of the aortic arch, through which a significant concentration of electrical potential power lines pass, makes the left leg most suitable for the lower influencing electrode. The arrangement of influencing electrodes in this manner guarantees the uniform distribution of influencing current power lines between measuring electrodes and thus helps to minimize the error in the final cardiac parameter measurements.

The upper pair of measuring electrodes may also be standard ECG spot electrodes with a contact area of 2 cm by 2 cm. These electrodes are placed symmetrically along the lateral lines of the patient's neck about the perimeter of the patient's neck 27, a distance S above the base of the neck. The distance S is defined as the distance between the base of the neck and the center 302 of electrode 22 and is preferably approximately 4 cm. The base of the neck is defined to be located at the point of maximum curvature of the lateral lines of the neck. Placing the upper measuring electrodes 22 in this area avoids the error that would otherwise result from the nonlinearity of electrical power lines at the neck-chest junction.

The lower chest pair of measuring electrodes 20 each have a contact area of 12 cm² to 30 cm². If this contact area is either reduced or enlarged, the heart stroke volume will be underestimated. A contact area of less than 12 cm² provides insufficient depth of measurement, a particularly serious problem with larger patients, and a contact area of more than 30 cm² causes the measurement to extend into additional anatomical regions.

The individual chest electrodes 20 are each preferably comprised of a set of four standard ECG spot electrodes 28, each with a contact area 29 of 2 cm by 2 cm with the top pair 34 of spot electrodes 28 of each chest electrode at xiphoid process level 38 (see FIGS. 2B and 4). All contact areas 29 are connected with foil or wire 31. The distance G separating adjacent spot electrodes is approximately 5 cm. The

-10-

contact areas 29 are placed on the body using a conductive gel, if not an integral feature of the spot electrodes 28. Such a design takes advantage of the anatomic features of zones I and III of the body (see FIGS. 3A and 3B) and insures a minimum of error since the measurement is taken at an adequate depth and allows for variations in the bodily constitutions of different patients. The chest electrodes 20 as described are placed laterally on opposite sides of the chest (see FIGS. 2A, 2B, and 2C) at the xiphoid process level 38. As shown in FIGS. 3A and 3B, placement is in zones II and IV, within an area anteriorly or posteriorly plus or minus about 10 centimeters of a lateral line extending through the body at xiphoid process level 38.

The influencing electrodes 24, 26 generate a high frequency, low amplitude current into the patient's body and the detecting electrodes 20, 22 measure the current after it passes through body tissue. The electrical impedance of the tissue can readily be determined from the difference between the generated current and the measured current. The electrical impedance of the tissue varies over time as a result of blood flow, respiration, and other factors.

The present invention also uses ECG signals concurrently measured with the bioimpedance signals. With the exception of post-measurement signal processing to remove hardware artifacts described below, the ECG signal measurement is performed in a conventional manner, and so will not be further described.

A preliminary step in the present invention is to determine the gain-phase-frequency (GPF) characteristics of the analog input devices (ECG converter and impedance converter) for subsequent use in signal processing.

A computer system, which may comprise a specifically programmed general purpose computer such as a personal computer, receives the electrical current measurements from the detecting electrodes 20, 22, determines both the impedance of the interceding tissue (bioimpedance) and the electric potential traversing the heart (ECG) as a function of time, and ultimately calculates HR (heart rate), SV (heart stroke volume), and CO (Cardiac Output). The equation for determining SV is given as follows:

$$SV = K \cdot P \cdot (L / Z_0)^2 \cdot \Delta Z$$

where K is a novel scale factor, P is the specific blood resistivity, L is the distance between the voltage measuring or sensing electrodes 20 and 22, Z_0 is the mean or base thoracic impedance (determined from sensing electrodes 20 and 22) and ΔZ , the impedance changes due to blood influx. ΔZ is calculated as

$$\Delta Z = ELVET \cdot (dZ/dt)_{\max} + Z_{s-q}$$

where $ELVET$ is the effective left ventricular ejection time, $(dZ/dt)_{\max}$ is the maximum absolute value of the time-differentiated impedance signal obtained from the two measuring electrodes, and Z_{s-q} is a novel correction factor that takes into account left-right ventricles asynchronism, equal to the bioimpedance difference between S and Q points (see FIGS. 13 and 14 and accompanying text).

The K term accounts for variations in body compositions of different patients. In order to obtain a value for the K factor, the medical practitioner first measures the height and weight of the patient and the perimeter of the patient's neck 27 and chest 36 using conventional means or commercially available ultrasonic measuring means. The medical practitioner then inputs these values into the computer system, which in turn uses the values to compute the effective cross-sectional area of the chest and the K factor. The effective cross-sectional area of the chest ($SCHEST$) is given by:

$$SCHEST = (PCHEST^2 + (PNECK \cdot PCHEST) + PNECK^2) / 12\pi,$$

where $PCHEST$ is the perimeter of the patient's chest 36 and $PNECK$ is the perimeter of the patient's neck 27. Then the K factor is calculated as follows:

$$K = K_0 - K_1 \cdot (SCHEST / (H^{K_2} \cdot W^{K_3})),$$

-12-

where H is the patient's height, W is the patient's weight, and K_0 , K_1 , K_2 , K_3 are gender and age dependent and lie in ranges

$$K_0 \in [1-4]; K_1 \in [3-16]; K_2 \in [0-1]; K_3 \in [0.1-2]$$

The present invention can thus be used on patients of varying body constitutions
5 without a loss of accuracy.

The electrical resistivity of human blood is not a constant. It varies among different individuals and even in the same individual at different times. Blood resistivity is particularly susceptible to fluctuation in patients undergoing blood infusion. As a result, an accurate system of bioimpedance cardiography must
10 include means for continuously modifying the blood resistivity term of the Kubicek equation.

A patient's specific blood resistivity depends largely upon his or her hematocrit. The relationship between these two values for capillary blood is as follows :

$$P=13.5+4.29 \cdot H,$$

15

where P is the specific blood resistivity and H is the capillary hematocrit. This relationship is adopted from V.I. Arinichin et al., "Taking into account electrical resistance of blood will increase accuracy of chest tetrapolar rheography method," Journal of Pediatrics (U.S.S.R.) 1987, v. 7, pp.59-52. The hematocrit can be
20 measured using any commercially available method. It may either be inputted into the computer system by the medical technician, or sent by electronic means directly from the hematocrit measuring device.

The invention utilizes a novel method for processing the ECG signal, (after hardware artifact removal) comprised of the following steps:

- 25
- (i) signal approximation from sampling points,
 - (ii) special filtering to highlight the positions of QRS complexes,
 - (iii) measuring peak-to-peak amplitudes for a given, recorded time interval,
 - (iv) calculation of amplitude threshold,

-13-

- (v) QRS selection with the calculated amplitude threshold,
- (vi) additional analysis of selected events to determine check point positions.

Step (i) above is desirable to increase the accuracy and reliability of QRS determination unless sampling frequency is extremely high. As a matter of practicability, such high frequency sampling is undesirable as consuming excessive processing time and memory capacity, and is impractical to effectuate the signals of restricted power spectrum. It is contemplated that two approaches to approximation may be suitable for use with the invention. First, it is well known that any signal $s(t)$ with finite spectrum (and defining the highest harmonic as $\omega_m = 2\pi f_m$), is fully described by its samples at points $s(n \cdot \Delta T)$, where $\Delta T \leq 1/2f_m$ is the sampling period, and n is an integer. A precise approximation of such a signal is given by the equation:

$$s(t) = \sum_{n=-\infty}^{\infty} s(n \cdot \Delta T) \frac{\sin \pi \cdot \left(\frac{t}{\Delta T} - n \right)}{\pi \cdot \left(\frac{t}{\Delta T} - n \right)} = \sum_{n=-\infty}^{\infty} s(n \cdot \Delta T) \varphi_n(t)$$

15 where $\varphi_n(t) = \text{sinc} \left(\pi \cdot \left(\frac{t}{\Delta T} - n \right) \right)$

The same result can be obtained in another way by first calculating a Fourier transform of the signal $s(t)$ and adding a small phase shift $\Delta\varphi$, to all harmonics, so that

$$\Delta\varphi/2\pi f = \tau = \text{const}, \quad \forall f.$$

Then, after calculation of the inverse Fourier transform, the approximated values of $s(t)$ at the points shifted by τ from the original samples are obtained. This latter approach is more efficient in calculation. Both methods permit lower sampling rates that lead to less consumption of memory and can be employed on demand to calculate a precise approximation of the original signal.

-14-

The next step is filtering the ECG signal to highlight the positions of QRS complexes. FIG. 10 illustrates a typical QRS complex, a signal peak with greatest amplitude measured from peak-to-peak in a single heartbeat. A symmetrical finite impulse response (FIR) digital filter is calculated from the desired gain-frequency characteristic (GFC_{filter}). The desired GFC_{filter} is elaborated from analysis of power spectrum of QRS complexes and has a passband from 6 Hz to 22 Hz with the maximum at 12.5 Hz. Using a discrete Fourier transform, the desired GFC_{filter} is converted to finite impulse characteristic according to an algorithm for filter synthesis described in V.S. Gutnikov, "Filtration of measured signals," Leningrad, 10 Energoatomizdat (USSR) 1990, pp. 172-181, incorporated herein by reference. This filter passes the QRS complexes and suppresses breath and movement artifacts in the ECG signal, also as P and T waves.

The next step is to calculate the peak-to-peak amplitude threshold and select valid QRS complexes. The computer system measures each local peak of the 15 filtered ECG signal by its front (E_1) and back (E_2) amplitude fronts, see FIG. 10. For each local peak, E_1 is the measured from the peak's anterior, or leading local minimum to the next nearest maximum, and E_2 is measured from the peak's maximum to its posterior, or trailing, minimum. FIG. 11 depicts a distribution (scatter diagram) of peaks by their (E_1 , E_2) coordinates for a time interval or period 20 of 10 seconds. FIG. 11 also shows the QRS complexes highlighted within a dotted circle in the lower right hand corner of the figure. Each peak is characterized by its (E_1 , E_2) vector and amplitude A_i , where

$$A_i = ((E_1)^2 + (E_2)^2)^{1/2}.$$

The computer system then searches the sorted $\{A_i\}$ array for the maximum difference between A_i and A_{i+1} . If the maximum is found for an exemplary k -th 25 element, then the amplitude threshold is calculated as $T = (A_k + A_{k+1})/2$. Thus, the QRS complex is detected in point j if A_j exceeds the threshold T . The threshold T is adapted for each 10 second block or interval of ECG data as $T_k = T_{k-1} + \alpha T_k$, where T_{k-1} is the adapted threshold for the previous data block, T_k is the calculated threshold for the current block, and α is a parameter of adaptation in the range of 30 0-1.

-15-

Each QRS complex identified by the use of the above "threshold" methodology is then further analyzed within an interval of -50 to +200 milliseconds (ms) from the determined QRS position. For each QRS complex identified, the computer system determines the amplitude, sequence of peaks, and derivative of peak fronts to arrange 3 check points (FIG. 12): the start of the QRS complex (P-point), the maximum deviation from the base-line (S_A -point, which coincides with peak R in a normal ECG), and the end of the QRS complex (S_B -point). These check points are used to refine the analysis of the bioimpedance signal described below.

The invention utilizes a novel method for processing the bioimpedance signal comprised of the following steps:

- (i) digital filtration and phase correction,
- (ii) heart rate estimation,
- (iii) suppression of breath waves,
- (iv) determination of cardiocycles,
- (v) arrangement of check points, and
- (vi) selection of cycles without interference artifacts.

The first part of the electronic filtration involves passing the signal through a "restoring" R-filter to achieve gain-phase-frequency (GPF) correction. The R-filter compensates for the distortions caused by the particular electronic transducer that is used to measure bioimpedance changes. It is well known that GPF characteristics of a bioimpedance transducer (FIG. 7) may greatly influence the shape of the bioimpedance curve. These interferences must be removed from the signal. The R-filter uses posterior signal processing to correct linear GPF distortions. It is constructed in such a way that the system of the bioimpedance transducer plus R-filter has GPF characteristics with zero phase shift and constant gain at the given range of frequencies, for example from 0.3 Hz to 30 Hz for the bioimpedance signal (see FIG. 8). Thus, correlation of the outputs of different bioimpedance devices may be achieved. With the exception of the filter parameters and operating characteristics specified as desirable or critical for the R-filter and other filters described herein, construction of same is conventional and within the ability of those skilled in the art, and so will not be further described.

-16-

The first step of the GPF correction involves connecting the bioimpedance transducer with a source of an electrically-generated sinusoidal impedance signal and then measuring the output from the transducer. The electronically-generated sinusoidal impedance signal has an amplitude of 0.1 Ohm to 0.2 Ohm with respect to a baseline, for example, 100 Ohm to 200 Ohm. Such a signal has been developed using a voltage-to-impedance converter consisting of a photoresistor, a photoemitter (photo diode), a power supply, and an analog-digital-analog (ADA) computer interface. The paired photoresistor and photoemitter are coupled inside a light-protected housing so that the photoresistor changes its impedance according to the photoemitter's light intensity. The ADA conversion process includes digital-to-analog conversion of the mathematically-modeled sinusoid with a frequency of 19 kHz and analog-to-digital conversion with a frequency of 100 Hz, with 12 bit resolution. Through the interface, the computer produces a set of test sinusoidal signals with frequencies in the range from 0 Hz to 75 Hz and records the responses of the transducer. The operating characteristics of the voltage-to-impedance converter include an input signal of 0 V to 5 V, an output signal of -0.1 Ohm to 0.1 Ohm with a baseline of 100 Ohm to 200 Ohm (as previously noted). The GPF characteristic $H(f)$ of the transducer may then be calculated from the spectrums of the initial test signals and the resulting responses of the transducer and presented as a graph or stored in an ASCII or other memory file. The system uses the calculated GPF characteristic $H(f)$ of the transducer to calculate the "restoring" R-filter. The GPF characteristic of such R-filter can be formally written as $1/H(f)$ in a certain frequency range. The R-filter also provides frequency bounds through low and high frequency filters to provide suppression of random low and high frequency interference (see FIG. 7). The filtration with the R-filter may be done in the frequency domain using a Fourier transform. It is preferable to use a Gaussian window with Fourier transform to eliminate the boundary effects of the recorded signal:

$$G(t) = \exp[-2(at/(2T))^2]$$

where $2T$ is a duration of recorded signal, $t < T$ is a time, and "a" is a predefined constant preferably in the range of 2.5-3. Multiplication of the Fourier image of the

-17-

recorded signal by the R-filter's GPF characteristics results in suppression of GPF distortions and additional filtration of the signal. Reverse Fourier transformation and division by the Gaussian window may also be employed. The same steps may be employed in the time domain without Fourier transformation. The signal after
 5 R-filtration is referred to as the "restored" signal, and this signal is used for further calculations.

It should also be noted at this time that the identified GPF characteristics of the ECG connection are processed to remove hardware artifacts from the ECG signal in a similar manner to that described above for the bioimpedance signal.
 10 GPF correction of both the ECG and bioimpedance signals promotes true correspondence of time intervals and event times between the two signals.

The next step in the bioimpedance signal processing is heart rate (HR) estimation. The present invention uses two ways to calculate HR. The ordinal way is to detect R-peaks on the ECG signal as described above and calculate R-R
 15 interval. The inverse value multiplied by 60 corresponds to heart rate. If ECG signal cannot be processed to detect R-peaks for some reason, the second way is used. In the second way, the power spectrum of the "restored" bioimpedance signal is calculated with discrete Fourier transform and used to estimate the patient's heart rate (HR). Very often a breath harmonic is the biggest one in the power spectrum
 20 of the bioimpedance signal. Consequently, it must be suppressed and the HR frequency response highlighted. A special transformation is used for this purpose. First, the power spectrum (PS) of the "restored" signal is multiplied with the gain-frequency characteristic of the A-filter (see FIG. 5A). This filter differentiates the signal and additionally suppresses harmonics below a certain frequency preferably
 25 selected at a range from 1 Hz to 3 Hz because breath wave harmonics commonly lie below 2 Hz and HR harmonics above 0.8 Hz. The power spectrum of clear cardio signal consists of repeated peaks at frequencies HR, 2*HR, 3*HR, etc. Consequently, the following autoconvolution of the power spectrum will emphasize the heart rate harmonic:

$$AS1(f) = PSa(f) \cdot PSa(2f) \cdot PSa(3f) \dots$$

-18-

where $AS1(i)$ is a result of the autoconvolution of the power spectrum and $PSa(i)$ is the power of a given spectral line with frequency i which previously passed through the A-filter. It is preferable to have in the above product only the first three elements PSa , because the higher the frequency is, the lower the signal-to-noise ratio. The computer system uses the autoconvolution to search for Mas , the maximum value of $AS1(i)$ in the range of 0.6 Hz to 5 Hz. The frequency associated with Mas is regarded as an estimation of HR. The estimation of HR is then used in additional filtration (see FIG. 5C) and cardiocycle-identification procedures.

10 The aberrations in the bioimpedance signal caused by respiration must be removed to increase accuracy and to insure proper identification of the cardiocycles. Usually, breath frequency is less than heart rate frequency, but breath waves create a power spectrum which overlaps the lowest harmonics of the power spectrum created by the cardiocycles. So, it is impossible to remove the breath waves' power spectrum from the summary power spectrum entirely (see FIG. 5C). Cardiac strokes are a more stable, repetitive process in comparison with breath. Consequently, we can consider that their power spectrum consists of several narrow peaks. All power spectrum harmonics between main cardiowaves' spectrum lines are combination of lateral slopes of these main spectrum lines and a noise power spectrum. If these internal harmonics are decreased, noise is mainly suppressed, and cardiowaves only slightly. As subsequently noted, these ideas form the basis for the algorithm for breath wave filtration. After estimation of the heart rate (HR), as described above, the first and second harmonics of the cardiowaves' spectrum are determined. The local minimums at the power spectrum nearest to these spectrum peaks can be considered as their bounds. All harmonics below the lower bound of the second peak except for those within the first peak bounds are multiplied by a predetermined value less than 1 (as schematically shown in FIG. 5C). This results in elimination of breath wave amplitude, because the latter's power spectrum lies in the multiplied zone, but only slightly affects the cardiowaves.

30 The next step in bioimpedance signal processing is cardiocycle detection. The invention also uses two ways to do this. The first way is to place the cardiocycle borders according to QRS complexes positions in the ECG signal. If the ECG cannot be processed, the second way is used. In the second way, the

"restored" signal as mentioned above is passed through the B-filter (FIG. 5B) to highlight the fronts of the cardiocycles. This is a differentiating filter with sinusoid-like frequency bounds. The pass band of the B-filter is adapted for frequency harmonics that produce a main contribution to cardiocycle front (preferably from 1 Hz to 6 Hz). The area between a local minimum and the next local maximum at the signal passed through the B-filter is regarded as a cycle front and described with a peak-to-peak change in time and a peak-to-peak change in amplitude. The computer system then generates a time-amplitude envelope by analyzing the first five (5) harmonics of the power spectrum generated by the signal after it passes through the B-filter. The cycle fronts are examined and certain ones are marked for further analysis if their peak-to-peak changes in time and peak-to-peak changes in amplitude are within the time-amplitude envelope. To increase the reliability of cardiocycles recognition, the computer system calculates mean and variance of peak-to-peak amplitudes for the selected regions.

If the variance-per-mean ratio is less than a predetermined value, preferably 0.3, then all of the marked fronts are transmitted to the next stage which involves the arrangement of check points and the selection of defect free cardiocycles. In the alternative, if the variance-per-mean ratio is greater than a predetermined value, then additional analysis must be performed. The additional analysis comprises the following steps: (i) the regions under examination are separated into two groups according to their peak-to-peak amplitude: those above the mean value ("the upper group") and those below the mean value ("the lower group"); (ii) the means, M1 and M2, and variances or standard deviations, V1 and V2, are calculated for each group; (iii) the appropriate values are inserted into the following inequality for each group:

$$M2 + a \cdot V2 < M1 - a \cdot V1,$$

where a is a predetermined value, preferably 1.96, and $V1$ and $V2$ are standard deviations for the lower and upper groups respectively; and (iv) if the inequality holds true, then the regions in the upper group are taken to be the fronts of the cardiocycles and the regions in the lower group are eliminated from further consideration, otherwise all selected regions proceed to the next stage.

-20-

The computer system identifies certain check points in the time-differentiated bioimpedance signal to calculate the effective left ventricular ejection time, ELVET, as a preliminary step in determining heart stroke volume (SV).

The present invention uses ELVET, a term which represents only the left
5 ventricular ejection time, rather than Kubicek's VET, a term which represents the combined left and right ventricular ejection times. It is known that the value of the time-differentiated impedance signal is proportional to peak aortic blood flow ejected by the left ventricle. Therefore, the most accurate calculation of SV requires that LVET be used. LVET is calculated from the following equation:

$$LVET = ELVET + LVPT,$$

10

where ELVET is the time between the moment the left ventricular valve opens (S-point) and the moment that it begins to close (T-point), and LVPT is the protodiastoly time (the time it takes for the left ventricular valve to close). LVPT is not readily detectable with hemodynamic monitoring means because the changes in
15 blood flow are insignificant during the protodiastoly time. For this reason, the present invention uses the product of ELVET and $(dZ/dt)_{max}$, the maximum absolute value of the first chest impedance derivative with respect to time, to account for the lack of an LVPT measurement.

The calculation of ELVET requires an analysis of the curve generated by the
20 graph of $Y(x)$, time-derivative bioimpedance, plotted with respect to time (see FIG. 9). The computer system first finds a global maximum of time-derivative impedance, $Y(x)$, over a given cardiocycle and designates it as point A. The computer system then traces back in time from the A-point to the point in time corresponding to the S_1 -point on the ECG signal, and looks for abnormalities in the
25 bioimpedance signal between those two points (see FIG. 12). The abnormalities of interest are: (1) dZ/dt zero crossing, (2) local minimum in dZ/dt , and (3) local maximum in the third derivative of the bioimpedance signal, d^3Z/dt^3 . If there is no abnormality in the bioimpedance signal found in the time interval between points A and S_1 , the cycle is considered defective and rejected from further consideration. If
30 any abnormalities are found to the right of S_1 , the abnormality closest to S_1 , approached from the right is selected as the ejection start time, S. Otherwise, the

abnormality closest to S_h approached from the left is selected as the ejection start time, S . The usage of the ECG signal increases stability of the S recognition in complex cases.

To identify the end of ELVET, point T , the computer system first finds point T_0 , which is taken to be either the first or the second local minimum after point A at the time differentiated bioimpedance signal, labeled as T_1 and T_2 respectively (see FIG. 9). The computer system chooses between T_1 and T_2 after an analysis of the depth (amplitude) of the curve at each point. If depth of the second minimum is greater than a predetermined fractional value of the depth of the first minimum, then T_2 is selected as T_0 . Otherwise, T_1 is used. To increase the stability of T_0 detection in noisy signals, the invention looks for the back or trailing edge of the T-wave in the ECG signal. The back edge of the T-wave is detected from the local maximum at ECG signal next to QRS complex up to the next local maximum at the graph of curvature of ECG signal versus time. If one of the points T_1 or T_2 is out of bounds of the T-wave's back, the other point is used as T_0 regardless of its amplitude. The "effective end" of the ventricular ejection, point T , is then identified as the nearest local minimum before point T_0 on the graph of the curve generated by the second derivative of $Y(x)$. ELVET is calculated as the time distance between points S and T .

The inventive method of determining ELVET has been correlated to an ultrasound ELVET determination with a correlation coefficient of $r = 0.86$. Kubicek's classic algorithm gives only a correlation of $r = 0.71$. See FIG. 15 for a graphic depiction of the correlations of the classic versus the new methodology to the ideal. Consequently, and in contrast to Kubicek, left ventricular ejection time as measured by the inventive method is measured in substantial isolation from the right ventricular ejection time.

Normally, the point of the ejection start, S , coincides with the zero crossing of the time-differentiated (dZ/dt) bioimpedance signal (see FIG. 13), but this is not the case for seriously ill patients (see FIG. 14). For such patients the point of the ejection start is often placed at the "stair" or "abnormality" of the first front of the bioimpedance signal. This "stair" or "abnormality" characteristic (also termed a "prewave") of an ill patient is commonly referred to as left-right ventricular asynchronism.

-22-

For healthy patients, the impedance value at the beginning of QRS complex at ECG (Q-point), Z_q is almost the same as the impedance value at the S-point, Z_s . This impedance difference is measured as Z_{s-q} (see FIG. 13). However, for ill patients, Z_{s-q} can be significant, (see FIG.14). Where Z_{s-q} is small, Kubicek's estimation of $\Delta Z = (dZ/dt)_{\max} \cdot VET$, is fairly accurate. For seriously ill patients exhibiting left-right ventricular asynchronism, however, the Kubicek equation generally underestimates ΔZ . Thus, the premise of the "prewave" should be accounted for in making the calculation. This invention compensates for the inherent underestimation of ΔZ in ill patients by adding the bioimpedance difference between S and Q points, Z_{s-q} to Kubicek's ΔZ estimation. By making this compensation, ΔZ is more accurately estimated, and the regression between bioimpedance and thermodilution cardiac output values is linearized. Thus, the computer system estimates ΔZ as

$$\Delta Z = (dZ / dt)_{\max} \cdot ELVET + Z_{s-q}$$

where Z_{s-q} is the bioimpedance difference between S and Q points.

After the computer system arranges all check points, it eliminates cardiocycles with certain aberrations. Fuzzy logic and fitness algorithms may be employed in this procedure. Several criteria are used for this purpose. The computer system first confirms that the time distances between the points described above for each cardiocycle (e.g., point A, point T, Point S) do not exceed certain bounds. It also verifies that the amplitude difference between the start and the end of the cardiocycle do not exceed a predefined value. The amplitude change between the start and end of the cardiocycle must not exceed a predefined percentage of the maximum amplitude over that cardiocycle. Furthermore, the ratio of the time-derivative bioimpedance signal amplitude at point A to the time-derivative bioimpedance signal at point T must be greater than a predetermined value; that is:

$$Y(A)/Y(T) > c,$$

-23-

where $Y(A)$ and $Y(T)$ are the values of the time-derivative bioimpedance signal at points A and T respectively, and "c" is the predetermined value. All cardiocycles that pass this stage are considered as "not very bad." The computer system then checks for the "neighbors criterion" to eliminate the effect of random noise in the bioimpedance signal. A three-dimensional "nearness" vector with elements ($A1_i$, $A2_i$, $A3_i$) is calculated for each pair of cardiocycles in a 10 second time block. The individual elements of the nearness vector are determined using the following equations:

$$A1_i = [Y(A_i) - Y(A_j)] / [Y(A_i) + Y(A_j)],$$

$$A2_i = (ST_i - ST_j) / (ST_i + ST_j),$$

10

and

$$A3_i = \frac{([Y(B_i) - Y(T_i)] - [Y(B_j) - Y(T_j)])}{([Y(B_i) - Y(T_i)] + [Y(B_j) - Y(T_j)])},$$

where $Y(x)$ is time-differentiated bioimpedance at a given point x, A, T, and B are check point positions in each cardiocycle (see FIG. 9); ST is the time between points S and T; and i and j are different cardiocycles. The computer system compares all of the calculated nearness vectors and eliminates those cardiocycles wherein the amplitudes of the nearness vectors exceeds certain thresholds. The comparison is made using a two-threshold analysis. If the nearness vector amplitude of two cardiocycles is less than a first predefined value, L1, the similarity is considered "good." If the similarity fails to be considered "good" (the similarity exceeds L1), but is still less than second predefined value, L2, it is considered as "acceptable." If the similarity fails to be considered "acceptable" for the 10 second block of data, the computer system compares the tested cardiocycle with up to 50 previous "not very bad" cycles. If there is still no cycle similar to the one being considered, the cycle under consideration is regarded as noisy, and is rejected. If

the amount of "good" cardiocycles is big enough, all "acceptable" cardiocycles also rejected from the final calculation. This methodology increases the stability of the calculations at the highest noise levels, as only "good" cardiocycles are used in the final calculations.

- 5 After the bioimpedance signal processing is complete, the computer system performs the final calculation of hemodynamic parameters, together with means and variances for the entire data block. Heart Rate (HR) and Heart Stroke Volume (SV) are recalculated using the respective methods described above, except that the processed bioimpedance signal is used instead of the unprocessed bioimpedance
10 signal. Cardiac Output (CO) is calculated as the product of HR and SV; that is:

$$CO=SV \cdot HR$$

An outline of the general methodology of the present invention is set forth in FIG. 6A. FIG. 6B depicts the flow chart of signal processing in the present invention.

- 15 While the present invention has been described in terms of a preferred embodiment, those of ordinary skill in the art will recognize and appreciate that it is not so limited. Many additions, deletions and modifications to the disclosed embodiment may be made without departing from the scope of the invention as hereinafter claimed.

-25-

CLAIMSWhat is claimed is:

1. An apparatus for determining a subject's heart rate, heart stroke volume, and cardiac output from detected thoracic bioimpedance signals and electrocardiogram comprising an electrode array for detecting said thoracic bioimpedance signals and said electrocardiogram.
2. The apparatus of claim 1 further comprising:
an upper influencing electrode placed on the subject's head;
a lower influencing electrode placed on the left lower extremity of the subject;
an upper pair of detecting electrodes placed on the subject's neck; and
a lower pair of detecting electrodes placed on the trunk of the subject.
3. The apparatus of claim 2, wherein the placement geometry further comprises:
an upper influencing electrode placed on the subject's forehead;
a lower influencing electrode placed in the general area of the subject's left knee;
a pair of upper detecting electrodes placed on the subject's neck; and
a pair of lower detecting electrodes placed laterally on opposite sides of the subject's chest.
4. The apparatus of claim 3, wherein said upper influencing electrode comprises a spot electrode for orientation on vertical and horizontal center lines of said subject's forehead.
5. The apparatus of claim 3, wherein said lower influencing electrode comprises a spot electrode, the placement of which satisfies the relationship $L < 5R$, where L is the vertical distance between said upper and said lower influencing electrodes and R is the radius of said subject's chest.
6. The apparatus of claim 3, wherein said upper detecting electrodes comprises a pair of spot electrodes oriented symmetrically on opposite sides of said

-26-

subject's neck along a horizontal line approximately 4 centimeters above the base of said subject's neck.

7. The apparatus of claim 3, wherein said lower detecting electrodes
5 further comprise a pair of electrode assemblies, each assembly providing contact surface area between about 12 square centimeters and about 30 square centimeters oriented laterally on opposite sides of said subject's chest at approximately xiphoid process level.

10 8. The apparatus of claim 7, wherein each assembly further comprises four spot electrodes, wherein each spot electrode comprises approximately 4 square centimeters contact surface area with each said spot electrode centered at corners of a square with sides measuring 5 centimeters, and all 4 spot electrodes of said assembly electrically connected to each other.

15

9. The apparatus of claim 8, wherein the top spot electrodes of each assembly lie on the xiphoid process level of the subject.

10. A method for processing a bioimpedance signal and
20 electrocardiogram for deriving heart rate, heart stroke volume, and cardiac output comprising:
registering gain-phase-frequency (GPF) characteristics of input analog devices for measuring bioimpedance;
registering gain-phase-frequency (GPF) characteristics of input analog devices for
25 measuring electrocardiogram;
measuring bioimpedance as a function of time over a given time period with said bioimpedance input analog devices and generating a bioimpedance signal;
measuring electrocardiogram as a function of time over said given time period with
said electrocardiogram input analog devices and generating an
30 electrocardiogram (ECG) signal;
correcting the bioimpedance signal for distortions based on the GPF characteristics previously registered;

-27-

correcting the electrocardiogram signal for distortions based on the GPF characteristics previously registered;

determining valid QRS complexes associated with each cardiocycle of said electrocardiogram signal in the given time period;

5 locating check-points on said valid QRS complexes;

processing one of said ECG signal and said corrected bioimpedance signal to estimate heart rate;

time-differentiating the corrected bioimpedance signal;

determining check-points for each said cardiocycle of the time-differentiated

10 bioimpedance signal in the given time period;

determining effective left ventricular ejection time (ELVET) using said time differentiated bioimpedance check-points in relation to said corresponding QRS check-points;

determining a novel correction factor Z_{-q} using said time differentiated

15 bioimpedance check-points in relation to said corresponding QRS check-points;

calculating stroke volume as a function of said ELVET, maximum time-differentiated bioimpedance $(dZ/dt)_{max}$, specific blood resistivity (P), distance (L) between two bioimpedance voltage sensing electrodes of the

20 bioimpedance analog input device, baseline bioimpedance (Z_0), said correction factor Z_{-q} , and a novel scale factor (K); and

calculating cardiac output by multiplying said stroke volume by said heart rate.

11. The method of claim 10, wherein said registering gain-phase-frequency (GPF) characteristics of said bioimpedance input analog devices comprises determining phase-frequency and gain-frequency characteristics of a transducer employed in detection of said bioimpedance prior to use thereof in said detection.

30 12. The method of claim 10, wherein said correcting of measured bioimpedance signal comprises digitally filtering and phase correcting said measured bioimpedance to remove distortion in the output of said transducer.

-28-

13. The method of claim 10, wherein said registering gain-phase-frequency (GPF) characteristics of said electrocardiogram input analog devices comprises determining phase-frequency and gain-frequency characteristics of a transducer employed in detection of said electrocardiogram prior to use thereof in said detection.

14. The method of claim 10, wherein said correcting of measured electrocardiogram signal comprises digitally filtering and phase correcting said measured electrocardiogram to remove distortion in the output of said transducer.

10

15. The method of claim 10, wherein said estimating heart rate comprises using a power spectrum of the bioimpedance signal, and an auto-convolution function of the said power spectrum.

16. The method of claim 10, wherein said estimating heart rate comprises processing the electrocardiogram signal.

17. The method of claim 12, wherein said correcting of measured bioimpedance signal further consists of suppressing breath waves to remove undesired power spectra components and generate a bioimpedance signal of restored shape.

18. The method of claim 10, wherein said determining valid QRS complexes comprises determining a distribution of all peaks measured in an electrocardiogram over a period of time (from the front (E_1) and back (E_2) amplitudes of the peaks, calculating the (E_1 , E_2) amplitude envelope and rejecting all peaks outside the envelope.

19. The method of claim 11, wherein said determining transducer phase-frequency and gain-frequency characteristics comprises:
generating a high precision sinusoidal impedance signal with peak-to-peak impedance of approximately 0.2 Ohms and baseline impedance of approximately 100 Ohms to 200 Ohms;

30

-29-

connecting said sinusoidal impedance signal to said transducer;
measuring the output from said transducer; and
calculating a gain-phase-frequency characteristic, $H(f)$, of the transducer in a
predefined frequency range.

5

20. The method of claim 19, further comprising generating said high
precision sinusoidal impedance signal using a voltage-to-impedance converter
including a photoresistor, a photoemitter, a power supply and an analog-to-digital-to
analog computer interface.

10

21. The method of claim 20, further comprising producing through said
interface a set of test signals with predefined amplitude and frequency range,
detecting an output signal from said transducer, and analyzing said output signal to
determine said phase-frequency and said gain-frequency characteristics.

15

22. The method of claim 19, further comprising employing posterior
signal processing to correct linear gain-phase-frequency distortions by converting
real operating characteristics of the transducer to predefined characteristics, wherein
phase shift is zeroed and gain is assumed to be constant in a predefined frequency
range.

20

23. A method of heart rate estimation, comprising:
calculation of a power spectrum of a bioimpedance signal;
multiplication of said power spectrum by a selected amplitude-frequency function to
differentiate the signal and suppress breath harmonics;
autoconvoluting the resulting power spectrum according to the formula

25

$$ASI(f) = PSa(f) \cdot PSa(2f) \cdot PSa(3f) \dots;$$

and

determining a maximum amplitude value of autoconvolution in a predefined
frequency range as an estimation of heart rate.

30

-30-

24. A method for determining cardiocycles, comprising:
filtering a bioimpedance signal to emphasize fronts of cardiocycles;
calculating a time-amplitude envelope of said cardiocycles by analyzing the first five
harmonics of the power spectrum of said bioimpedance signal after said
5 filtration;
selecting said cardiocycle fronts by comparison with said calculated time-amplitude
envelope; and
rejecting erroneously-detected fronts.
- 10 25. A method of selecting valid cardiocycles from corrected
bioimpedance signals to eliminate cardiocycles having interference artifacts,
comprising:
detecting time and amplitude relations referencing check points within individuals of
a plurality of cardiocycles;
15 comparing said time and amplitude relations between individuals of a said plurality
of cardiocycles; and
further examining selected cardiocycles which exhibit the presence of artifacts
according to a plurality of comparison criteria.
- 20 26. The method of claim 25, further comprising:
constructing a multi-dimensional vector for each selected cardiocycle;
comparing said multi-dimensional vector with such vectors for other cardiocycles
and;
rejecting the cardiocycles with vectors having no neighboring vectors when
25 compared to last 50 valid cardiocycles and other candidate cardiocycles.
27. A method of deriving effective left ventricular ejection time from
measured bioimpedance signal and measured electrocardiogram signal, comprising:
filtering said measured bioimpedance signal and suppressing breath waves therein;
30 filtering said measured electrocardiogram signal;
detecting a valid cardiocycle;
calculating the time-derivative of said bioimpedance signal $Y(x)$;
determining the maximum value of the time-derivative $(dZ/dt)_{max}$;

-31-

determining effective ejection start time (S-point);
determining effective ejection end time (T-point); and
calculating effective left ventricular ejection time (ELVET) as change in time
between effective ejection start time and end time.

5

28. The method of claim 27, wherein determining effective ejection start time comprises:

determining the global maximum for a given valid cardiocycle of a time-

differentiated bioimpedance signal and designating said maximum as point A;

10 tracing back in time from corresponding point A on electrocardiogram to point S_0 ;

looking for abnormalities in the bioimpedance signal between points A and S_0 ;

if there are no said abnormalities, then the cardiocycle is rejected as noisy;

if there are any said abnormalities the one closest to point S_0 approached from the right is selected as the ejection start time S;

15 otherwise the abnormality nearest S_0 approached from the left is selected as the ejection start time S.

29. The method of claim 28, wherein determining effective ejection end time comprises:

20 determining the first (T_1) and second (T_2) local minimums at the time-differentiated bioimpedance signal after point A;

analyzing the depth of the signal curve at each of the first (T_1) and second (T_2) local minimums;

25 if the depth of the second (T_2) minimum is greater than a predetermined fractional value of the depth of the first (T_1) minimum, selecting the second minimum (T_2) as T_0 ;

otherwise, selecting T_1 as T_0 ; and

identifying the T-point as the nearest local minimum before point T_0 on the graph of the curve generated by the second derivative of $Y(x)$.

30

30. The method of claim 29, further comprising, after identifying T_1 and T_2 and before identifying the T-point and regardless of relative amplitudes of T_1 and T_2 :

-32-

detecting a back edge of a T-wave in the electron cardiogram signal;
 determining if T_1 or T_2 is out of bounds of the back of the T-wave; and
 if so, selecting the one of T_1 or T_2 which is not out of bounds as T_0 .

- 5 31. In the method of claim 28, abnormalities are selected from the group comprising: dZ/dt zero crossing (Q-point), local minimum in dZ/dt , and local maximum in the third time-derivative of the bioimpedance signal, d^3Z/dt^3 .

32. A method of determining stroke volume for a patient, comprising:
 10 determining specific blood resistivity P ;
 measuring a distance L between two bioimpedance electrodes applied to the patient;
 determining the base thoracic impedance Z_0 ;
 determining ELVET;
 determining ΔZ , impedance changes due to blood influx;
 15 and calculating stroke volume SV according to the equation

$$SV = K \cdot P \cdot (L/Z_0)^2 \cdot \Delta Z,$$

where K is a novel scale factor related to body composition of the patient.

20

33. The method of claim 32, further comprising calculating K as

$$K = K_0 - K_1 \cdot (SCHEST / (H^{K_2} \cdot W^{K_3})),$$

where

$$SCHEST = (PCHEST^2 + PNECK \cdot PCHEST + PNECK^2) / 12\pi.$$

- 25 34. The method of claim 33, wherein K_0 , K_1 , K_2 , K_3 are gender and age dependent and lie in ranges of

-33-



$$K_0 \in [1-4]; K_1 \in [3-16]; K_2 \in [0-1]; K_3 \in [0.1-2].$$

35. A method of claim 32, wherein determining ΔZ comprises:
- locating the start of QRS complex of an ECG signal and labeling it point Q;
 - determining the impedance at point S, Z_s ;
 - determining the impedance at point Q, Z_q ;
 - 5 calculating the impedance difference Z_{s-q} between points S and Q;
 - estimating ΔZ according to the formula

$$\Delta Z = (dZ / dt)_{\max} \cdot ELVET + Z_{s-q}$$

36. A method of breath wave suppression for a bioimpedance signal, comprising:
- 10 calculating the Fourier transform of the signal;
 - locating the first and second frequency harmonics of cardiocycles in the calculated spectrum of the signal;
 - estimating the width of each of the harmonics;
 - suppressing frequency harmonics below the lower bound of the second harmonic
 - 15 except for harmonics within the bounds of the first frequency harmonic; and
 - calculating the inverted Fourier transform of the signal.

1/10

**Fig. 1****Fig. 2A**

2/10




Fig. 2B




Fig. 2C




Fig. 3B




Fig. 3A

3/10




Fig. 4




Fig. 5A




Fig. 5B




Fig. 5C

4/10




Fig. 6A

5/10




Fig. 6B

6/10




Fig. 7A

Fig. 7B




Fig. 7C





Fig. 7D



7/10




Fig. 8A




Fig. 8B




Fig. 9

8/10




Fig. 10




Fig. 11




Fig. 12

9/10




Fig. 13




Fig. 14

10/10




Fig. 15

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/SG 97/00013

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61B5/08 A61B5/05

According to International Patent Classification (IPC) or to both national classification and IPC:

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 84 00227 A (BOMED MEDICAL MANUFACTURING LTD.) 19 January 1984	1
A	see page 5, line 25 - page 6, line 11 see page 7, line 26 - page 8, line 20 ---	2,3,6
X	US 4 807 638 A (B. SRAMEK) 28 February 1989	1,2
A	see column 3, line 65 - column 4, line 54 see column 9, line 21 - column 10, line 43 ---	3,6,9
X	WO 93 04627 A (DREXEL UNIVERSITY) 18 March 1993	1
A	see page 13, line 6 - page 14, line 11 see page 16, line 5 - page 17, line 19 ---	2,3,6
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

- * "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- * "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- * "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- * "&" document member of the same patent family

Date of the actual completion of the international search

8 August 1997

Date of mailing of the international search report

18.08.97

Name and mailing address of the ISA

European Patent Office, P.O. Box 5818 Patentplan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Geffen, N

INTERNATIONAL SEARCH REPORT

Intern. Application No
PCT/SG 97/00013

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 89 01312 A (BOMED MEDICAL MANUFACTURING LTD.) 23 February 1989 see page 2, line 34 - page 3, line 27 see page 7, line 19 - line 23 ---	1
X	US 5 178 154 A (J.J. ACKMANN ET AL) 12 January 1993	1
A	see column 3, line 33 - line 45 ---	2-4
A	US 4 016 868 A (R.D. ALLISON) 12 April 1977 see column 1, line 13 - line 53 see column 3, line 31 - line 42 -----	1-3

INTERNATIONAL SEARCH REPORT

national application No.

PCT/SG 97/00013

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 10-36
because they relate to subject matter not required to be searched by this Authority, namely:
PCT Rule 39.1 (iv)
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/SG 97/00013

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8400227 A	19-01-84	US 4450527 A AU 1822483 A CA 1184654 A EP 0112904 A	22-05-84 26-01-84 26-03-85 11-07-84
US 4807638 A	28-02-89	CA 1327388 A EP 0441777 A JP 3504202 T WO 8903656 A	01-03-94 21-08-91 19-09-91 05-05-89
WO 9304627 A	18-03-93	US 5309917 A EP 0606301 A JP 7503380 T US 5423326 A US 5443073 A	10-05-94 20-07-94 13-04-95 13-06-95 22-08-95
WO 8901312 A	23-02-89	US 4870578 A JP 2500887 T	26-09-89 29-03-90
US 5178154 A	12-01-93	NONE	
US 4016868 A	12-04-77	NONE	